Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENOtype trial

William J Anderson; Philip Short; Peter A Williamson; Brian J Lipworth

doi:10.1378/chest.12-1310

Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENOtype trial

William J Anderson, Philip Short, Peter A Williamson, Brian J Lipworth

Research output: Contribution to journal › Article › peer-review

58 Citations (Scopus)

Abstract

International guidelines advocate a standard approach to asthma management for all, despite its heterogeneity. "Personalized" treatment of inflammatory asthma phenotypes confers superior benefits. We wished to evaluate dose response to inhaled corticosteroids (ICSs) in patients with asthma with an elevated fractional exhaled nitric oxide (Feno) phenotype using domiciliary measurements.

Original language	English
Pages (from-to)	1553-61
Number of pages	9
Journal	Chest
Volume	142
Issue number	6
DOIs	https://doi.org/10.1378/chest.12-1310
Publication status	Published - Dec 2012

Access to Document

10.1378/chest.12-1310

Cite this

@article{5a23013a83bf475f863ced42e71ce3a3,

title = "Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENOtype trial",

abstract = "International guidelines advocate a standard approach to asthma management for all, despite its heterogeneity. {"}Personalized{"} treatment of inflammatory asthma phenotypes confers superior benefits. We wished to evaluate dose response to inhaled corticosteroids (ICSs) in patients with asthma with an elevated fractional exhaled nitric oxide (Feno) phenotype using domiciliary measurements.",

author = "Anderson, {William J} and Philip Short and Williamson, {Peter A} and Lipworth, {Brian J}",

year = "2012",

month = dec,

doi = "10.1378/chest.12-1310",

language = "English",

volume = "142",

pages = "1553--61",

journal = "Chest",

issn = "1931-3543",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma

T2 - the FENOtype trial

AU - Anderson, William J

AU - Short, Philip

AU - Williamson, Peter A

AU - Lipworth, Brian J

PY - 2012/12

Y1 - 2012/12

N2 - International guidelines advocate a standard approach to asthma management for all, despite its heterogeneity. "Personalized" treatment of inflammatory asthma phenotypes confers superior benefits. We wished to evaluate dose response to inhaled corticosteroids (ICSs) in patients with asthma with an elevated fractional exhaled nitric oxide (Feno) phenotype using domiciliary measurements.

AB - International guidelines advocate a standard approach to asthma management for all, despite its heterogeneity. "Personalized" treatment of inflammatory asthma phenotypes confers superior benefits. We wished to evaluate dose response to inhaled corticosteroids (ICSs) in patients with asthma with an elevated fractional exhaled nitric oxide (Feno) phenotype using domiciliary measurements.

U2 - 10.1378/chest.12-1310

DO - 10.1378/chest.12-1310

M3 - Article

C2 - 23364390

SN - 1931-3543

VL - 142

SP - 1553

EP - 1561

JO - Chest

JF - Chest

IS - 6

ER -

Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENOtype trial

Abstract

Access to Document

Fingerprint

Cite this